Pierce Kristen K, Whitehead Stephen S, Kirkpatrick Beth D, Grier Palmtama L, Jarvis Adrienne, Kenney Heather, Carmolli Marya P, Reynolds Cynthia, Tibery Cecilia M, Lovchik Janece, Janiak Anna, Luke Catherine J, Durbin Anna P, Pletnev Alexander G
Robert Larner MD College of Medicine at the University of Vermont, Burlington.
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.
West Nile virus (WNV) is a major cause of mosquito-borne illness in the United States. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults aged >60 years are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated West Nile virus vaccine, rWN/DEN4Δ30, was shown to be safe and immunogenic in healthy adults aged 18-50 years. This study evaluated rWN/DEN4Δ30 in flavivirus-naive adults aged 50-65 years and found it to be safe and immunogenic. Outbreaks of WNV infection tend to be unpredictable, and a safe and effective vaccine will be an important public health tool.
西尼罗河病毒（WNV）是美国蚊媒疾病的主要病因。人类疾病范围从轻度发热疾病到严重的致命性神经感染。60岁以上的成年人更容易患神经侵袭性疾病，伴有高死亡率或长期神经后遗症。一种嵌合减毒活西尼罗河病毒疫苗rWN/DEN4Δ30，在18至50岁的健康成年人中显示出安全且具有免疫原性。本研究评估了rWN/DEN4Δ30在50至65岁未感染黄病毒的成年人中的情况，发现它安全且具有免疫原性。西尼罗河病毒感染的爆发往往不可预测，一种安全有效的疫苗将是一项重要的公共卫生工具。
